Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill

Current Hypertension Reports

Volumn 18, Issue 5, 2016, Pages

  Lafeber, M ^a   Spiering, W ^a   Visseren, F L J ^a   Grobbee, D E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adherence; Cholesterol; Combination pill; Fixed dose combination therapy; Hypertension; Polypill; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; ENALAPRIL; FOLIC ACID; HYDROCHLOROTHIAZIDE; LISINOPRIL; RAMIPRIL; SIMVASTATIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG MARKETING; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW RISK POPULATION; PILL; POLYPHARMACY; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 84963746238     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-016-0648-3     Document Type: Review

References (43)

1. GBDRF Collaborators, Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–323.
2. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377(9765):568–77.
3. Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17):2143–52.
4. Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37(3):869–74.
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.
6. Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–8.
7. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
8. World Health Organization. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011.
9. Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133. Most recent large multinational observational cohort demonstrating suboptimal treatment achievement in patients with coronary artery disease.
10. Browne JL, Grobbee DE. Cardiovascular prevention and international health: time for action. Eur J Cardiovasc Prev Rehabil. 2011;18(4):547–9.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
13. Gorostidi M, de la Sierra A. Combination therapy in hypertension. Adv Ther. 2013;30(4):320–36.
14. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.
15. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16.
16. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14–26.
17. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
18. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13(12):898–909.
19. Gould RJ, Nichtberger SA, Rhymer PA, Olofsson L, Inventors combination therapy for reducing the risks associated with cardiovascular disease patent WO 98/11896. 1998 26-03-1998.
20. Tobert JA, inventor. Combination therapy for reducing the risks associated with cardiovascular disease. Patent WO 9738694 1997 23-10-1997.
21. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
22. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
23. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005;365(9457):434–41.
24. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
25. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
26. Group SR, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. Recent trial showing more intensive blood pressure treatment goals might be beneficial in cardiovascular events in patients with hypertension.
27. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.
28. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.
29. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.
30. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–29.
31. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010;64(9):1220–7.
32. Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011;6(5):e19857.
33. Lafeber M, Webster R, Visseren FL, Bots ML, Grobbee DE, Spiering W, et al. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. Eur J Prev Cardiol. 2016.
34. Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes. 2012;5(4):463–71.
35. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.
36. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve the use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2014.
37. Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2015;205:147–56. A recent meta-analysis of three participant individual data and a meta-analysis of the three recent polypill trials (UMPIRE, Kanyini-GAP and IMPACT).
38. Smith R, McCready T, Yusuf S. Combination therapy to prevent cardiovascular disease: slow progress. JAMA. 2013;309(15):1595–6.
39. Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2014;181C:193–9.
40. Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol. 2015;201 Suppl 1:S15–22. Article concerning the only currently available polypill.
41. Ebrahim S, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews [Internet]. 2006; (4). Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001561/frame.html; http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001561.pub2/abstract.
42. Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011;12:3.
43. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7):e41297.